SMi Group announces the 10th Annual RNA Therapeutics Conference

SMi Group20 - 21 February 2019, London, UK.
Undoubtedly, the field of RNA therapeutics is currently undergoing a major expansion, and the potential for using RNA drugs for personalised medicines and immunotherapy, as well as to address genetic, infectious and chronic diseases will ensure the continued development of RNA therapeutics for years to come.

Fulfilling the potential of genetic discoveries requires the development of therapeutics that can specifically modulate the expression of disease-relevant genes. RNA-based drugs, including siRNAs and antisense nucleotides, are promising examples of a newer class of biologics. Researchers have tried to overcome the major challenges for utilising RNAs in a therapeutic context, including: intracellular delivery, stability and immunogenicity.

Join the 10th Annual RNA Therapeutics Conference in February 2019, for SMi's 10th annual sell out event. Bringing together industry experts from leading RNA companies, to discuss the challenges for clinical translation of RNA-based therapeutics, with an emphasis on recent advances in delivery technologies, and present an overview of the applications of RNA-based drugs for modulation of gene and protein expression, and genome editing.

Network and learn from key opinion leaders such as:

Chairs for 2019

  • Ekkehard Leberer, Senior Director, Alliance Management, Sanofi
  • Shalini Andersson, Senior Director and Head of New Modalities, AstraZeneca

Guest Speakers

  • Carsten Rudolf, Chief Executive Officer, EthrisGmbh
  • Paul Agris, Founder and Director, The RNA Institute

Keynote Speakers

  • Marian Gindy, Executive Director, Pharmaceutical Sciences, Merck Research Labs, Merck & Co, inc.
  • David Giljohan, CEO, Exicure
  • Ingmar Hoerr, Founder & CEO, CureVac AG
  • David Blakey, Chief Scientific Officer, MiNA Therapeutics
  • André Gerber, Professor of RNA Biology, University of Surrey
  • Heinrich Haas, Vice President Drug Delivery, BioNTech RNA Pharmaceuticals
  • Markus Mandler, Chief Scientific Officer, Accanis Biotech
  • Troels Koch, Vice President & Head of Research, RNA Therapeutics, Roche
  • Hans Kistemaker, Associate Director, ProQR

2019 Featured Highlights

  • Discover the clinical progress of Spherical Nucleic Acids at Exicure
  • Understand Sanofi's strategies to deliver therapeutic oligonucleotides across biobarriers
  • Learn from ProQR how to plan for oligonucleotide supply from personalized medicine to large scale markets
  • Explore the development of small activating RNA - from bench to bedside with MiNA Therapeutics
  • Gain insight into the discovery and development of self-amplifying mRNA vaccines at GSK

For further information and to register, please visit:
http://www.therapeutics-rna.com/wpn

Early-Bird Rates

  • Register by 31st October and save £400
  • Register by 30th November and save £200
  • Register by 15th December and save £100

About SMi Group

The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

Imfinzi is the first immunotherapy to demonstrate …

AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi durin...

Sandoz Healthcare Access Challenge #SandozHACk ret…

Sandoz, the Novartis generics and biosimilars division, today announces the launch of the second Sandoz Healthcare Access Challenge (HACk). The #SandozHACk is a global co...

Global survey reveals that physicians need more in…

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make inf...

In clinical trials, new antibody therapy controls …

Thanks to improvements in antiretroviral therapy, HIV is now a manageable condition. Yet even the best drugs do not entirely eliminate the virus, which latently lingers i...

Novartis licenses three novel anti-infective progr…

Novartis announced today that it has entered into a licensing and equity agreement with Boston Pharmaceuticals for the development of three novel anti-infective drug cand...

The Nobel Prize in Physiology or Medicine 2018 was…

Cancer kills millions of people every year and is one of humanity's greatest health challenges. By stimulating the inherent ability of our immune system to attack tumor c...

Pfizer to award more than $3 million in grants to …

Pfizer Inc. today announced the recipients of the Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Breast Cancer Research Awards. Four grants tota...

FDA approves first treatment for advanced form of …

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squam...

DNA islands effective as 'anti-bacterial drones'

Genomic "islands" that evolved from viruses can be converted into "drones" that disable Staphylococcus aureus, bacteria that are often resistant to antibiotics and pose a...

FDA awards 12 grants to fund new clinical trials t…

The U.S. Food and Drug Administration today announced that it has awarded 12 new clinical trial research grants totaling more than $18 million over the next four years to...

Addressing social and cultural drivers of type 2 d…

New research shows healthcare services and public health strategies aimed at reducing the burden of type 2 diabetes may prove ineffective, unless they address social and ...

Evidence mounts linking aspirin to lower risk of o…

Taking a low-dose aspirin daily may help women lower their risk of developing ovarian cancer. A new study co-led by Moffitt Cancer Center found that women who reported ta...